An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer

Published:2022-03-10 Issue:6 Volume:23 Page:647-652
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Wang Jingyi¹^ORCID,Wu Lin¹^ORCID

Affiliation:

1. The Second Department of Thoracic Oncology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, P. R. China

Funder

Hunan Provincial Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2050213

Reference29 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

4. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

5. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells;Clinical and Translational Oncology;2024-05-30

2. Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review);Molecular and Clinical Oncology;2024-02-09

3. Anti-cancer effects of bis-oxidized thiopyran derivatives on non-small cell lung cancer: rational design, synthesis, and activity evaluation;New Journal of Chemistry;2024

4. Non-small cell lung cancer with bone metastasis and pneumocystis pneumonia in a pregnant woman: a case report and literature review;BMC Infectious Diseases;2023-11-14

5. EGFR/HER Family Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08